For the near term, we are going to be in this limited availability, which may cause delays across some of the doses for both Mounjaro and Zepbound. We are working so hard every day to make sure that we increase that capacity as fast as we can to get these medications in patients' hands.
The shortage primarily affects two of the six approved doses of injectable Zepbound: the 5 mg and 12.5 mg variants. Limited availability of these doses is expected to persist until the end of April, attributing the scarcity to the heightened demand for the drug.
The remaining four doses-2.5 mg, 7.5 mg, 10 mg, and 15 mg-are currently unaffected by availability issues, ensuring continued access for consumers seeking the medication.
Zepbound, previously marketed as Mounjaro, is approved by the FDA as a weight loss treatment, aiming to assist individuals with obesity or overweight conditions and weight-related health complications like type 2 diabetes and hypertension.
[
add
]
[
|
|
...
]